Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,461 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,461 shares of Stoke Therapeutics stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider owned 40,702 shares of the company’s stock, valued at $1,220,652.98. The trade was a 3.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total transaction of $203,473.64.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $34.41 on Friday. The firm’s 50 day simple moving average is $32.60 and its 200-day simple moving average is $29.93. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $40.22. The firm has a market cap of $2.04 billion, a PE ratio of 51.46 and a beta of 1.07.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on STOK shares. Needham & Company LLC lifted their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Thursday. HC Wainwright lifted their price objective on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. Finally, Wedbush increased their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.83.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
• Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. increased its holdings in shares of Stoke Therapeutics by 24.7% in the 4th quarter. Invesco Ltd. now owns 259,543 shares of the company’s stock valued at $8,238,000 after acquiring an additional 51,468 shares during the period. NewEdge Advisors LLC bought a new position in shares of Stoke Therapeutics in the 4th quarter worth $330,000. Tudor Investment Corp ET AL purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth $613,000. Readystate Asset Management LP bought a new stake in Stoke Therapeutics during the fourth quarter valued at about $922,000. Finally, RTW Investments LP grew its stake in Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after purchasing an additional 423,331 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.